Medical News Today -
2 Oct 2013 11:00
UCB has announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia® (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA). "The FDA's approval of Cimzia® for the treatment of active PsA provides an additional, effective treatment option for those living with the condition. Psoriatic arthritis brings with it a heavy disease burden that often strikes during the prime years of life, impacting health-related quality of life and physical ...
Share this Article